The battle between the FTC and generic drug company Watson Pharmaceuticals over whether the company engaged in an anti-competitive deal with Frazer, Pa.-based Cephalon continues in a Washington court as the FTC fired back responses defending its actions during the investigations.
After a magistrate judge for the U.S District Court for the District of Columbia, in a rare move, ordered the U.S. Federal Trade Commission to respond to interrogatories by Watson CEO Paul Bisaro about why the FTC was seeking his testimony, the FTC answered the questions and gave a little extra. And Watson quickly issued a response.
